A Phase 2 interventional study of Belatacept and Cyclosporine A in Renal Transplant, sponsored by Bristol-Myers Squibb. Completed at 44 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-05.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to learn if conversion to belatacept from cyclosporine or tacrolimus will preserve kidney function in people who have had a kidney transplant. The safety and tolerability of this treatment will also be studied
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Belatacept
Drug: Cyclosporine A · Drug: Tacrolimus
IV, IV Infusion, 5 mg/kg once every 28 days for one year
Also known as: BMS-224818
Tablets, Oral, Trough of 100-250 ng/mL, 2\* daily for one year
Tablets, Oral, Trough of 5-10 ng/mL, 2\* daily for one year
Mean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 12 Months Post Randomization - All Randomized Participants (Intent-to-Treat Population)
Calculated GFR assessment used the modification of diet in renal disease (MDRD) formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value 10 was used, for other participants who had a post baseline cGFR value missing, but had baseline value and at least 2 post baseline values available, which were at least 120 days apart, linear regression model was used to impute the cGFR value. Baseline = value at screening. Randomization/First Dose was on Day 1.
Time frame: Baseline to 12 months post randomization
Mean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 6 Months Post Randomization - All Randomized Participants (Intent-to-Treat Population)
Calculated GFR assessment used the modification of diet in renal disease (MDRD) formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value 10 was used, for other participants who had a post baseline cGFR value missing, but had baseline value and at least 2 post baseline values available, which were at least 120 days apart, linear regression model was used to impute the cGFR value. Baseline = value at screening.
Time frame: Baseline to 6 months post randomization
Number of Participants With Acute Rejection (AR) by Months 6 and 12 Post Randomization - All Randomized Participants
AR defined: if either a or b was satisfied: a: the reason for clinical suspicion was reported to be an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness and the episode was a case of biopsy proven AR (AR of Banff histopathologic classification Grade IA or higher as assessed by the blinded central pathologist); b: the reason for clinical suspicion was reported to be something other than: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness; the episode was a case of biopsy proven AR, and the participant was treated for this episode. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. AR is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection.
Time frame: At 6 and 12 months post randomization
Percentage of Participants Surviving With a Functioning Graft, Have Graft Loss or Death (Graft Loss, Death, Death With Functioning Graft) By Month 6 and Month 12 Post Randomization
Graft loss was defined as either functional loss or physical loss. Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 mg/dL (530 μmol/L) for ≥ 4 weeks or administration of a maintenance dialysis regimen for at least 56 days or impairment of renal function to such a degree that the participant undergoes re-transplantation.
Time frame: At 6 and 12 months post randomization
Number of Participants Who Had Any Study Drug Dose Alteration by Month 12 Due to Any Reason - Randomized and Treated Participants
Reasons for study drug dose modification included categories of decline in renal function (as determined by the investigator), treatment of acute rejection, and other reasons. More than 1 reason could be given for dose alteration.
Time frame: Month 12
Percentage of Participants With a Composite Endpoint of Death, Graft Loss and Acute Rejection at Month 12
Percentage=number with composite divided by number randomized. Graft loss was functional loss or physical loss. Functional loss = sustained level of serum creatinine (SCr) ≥ 6.0 mg/dL for ≥ 4 weeks or administration of a maintenance dialysis regimen for at least 56 days or impairment of renal function to such a degree that participant undergoes re-transplantation. AR: if either a or b: (a) the reason for clinical suspicion was reported to be an unexplained rise of serum creatinine ≥ 25% from baseline; or an unexplained decreased urine output; or fever and graft tenderness and the episode was a case of biopsy-proven AR (grade IA or higher as assessed by the blinded central pathologist); (b) the reason for clinical suspicion was reported to be something other than: an unexplained rise of serum creatinine ≥ 25% from baseline; or an unexplained decreased urine output; or fever and graft tenderness; the episode was a case of biopsy-proven AR, and the participant was treated for it.
Time frame: 12 Months post randomization
Percentage of Participants With New Onset Diabetes Mellitus - All Randomized Participants
A participant who did not have diabetes prior to randomization is determined to have new onset diabetes mellitus if they received an antidiabetic medication for a duration of at least 30 days or at least two fasting plasma glucose (FPG) tests indicated that FPG is \>=126 mg/dL. Percentage was the number of participants with new onset of diabetes mellitus divided by the number of participants without pre-randomization diabetes.
Time frame: Month 12 post randomization
Number of Participants With Anti-Donor Human Leukocyte Antigen (HLA) Positive Antibodies
Samples were obtained at Day 1 (first dose), Week 24, and Week 52 (or end of therapy). This was a cumulative summary in that once a participant was positive, that participant remained positive for later time points. Evaluation of anti-donor HLA antibodies was performed by an external laboratory (Emory University, Atlanta, Georgia).
Time frame: Month 6 and Month 12 Post Randomization
Mean Change From Baseline to Month 6 and to Month 12 in Serum Creatinine - All Randomized Participants
Baseline was value at screening or prior to first dose of study drug. Serum creatinine was measured in milligrams per deciliter (mg/dL). Baseline = value at screening.
Time frame: Baseline to Month 6 and Month 12 Post Randomization
Number of Participants With Serious Adverse Events (SAEs), Deaths, and Discontinuation Due to Adverse Events (AEs) From First Dose up to Month 12
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.
Time frame: First Dose (Day 1) to Month 12
Mean Change From Baseline in SF-36 Questionnaire Physical Component Score and in Mental Component Score at Month 12 - All Randomized Participants
SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire. The subscale in the mental component (MCS) part of the instrument ranged from 1 to 6 with 1=all of the time and 6= none of the time. The subscale for physical component (PCS) ranged from 1 to 3 with 1=Yes, limited a lot and 3=No, not limited at all. The subscale for the extent that physical health or emotional problems interfered with normal activities ranged from 1 to 5 with 1=not at all and 5= extremely. Baseline was at randomization or prior to first dose. Baseline = value at screening. The subscale scores were transformed using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life.
Time frame: Baseline, Month 12
Mean Change From Baseline to Month 12 for Eight Domain Scores of Quality of Life (QoL) Instrument SF-36 - All Randomized Participants
SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 8 domains of physical and mental component summaries: physical function, role limitations due to physical problems, pain, general health perception, and vitality, social function, role limitations due to emotional problems, and mental health. All domains were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life.
Time frame: Baseline (screening) to Month 12
Ridit Score at Month 12 - All Randomized Participants
The Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-59R) was used to assess the occurrence (never, occasionally, regularly, almost always, always) and distress (0=no distress to 4=terrible distress) of symptoms associated with immunosuppressive therapies. Ridit (relative to an identified distribution) analysis (Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley \& Sons, Inc. 1991) was used. Ridit scores were calculated at 12 months for overall symptom occurrence score and overall symptom distress. The Ridit score reflects the probability that a score observed for an individual randomly selected from a group would be higher (worse symptom) than a score observed for a randomly selected individual from the reference group. The reference group was constituted by the frequency distribution of the responses of all participants on all items at baseline. The ridit of the reference group is by definition, 0.5.
Time frame: Month 12
Number of Participants Meeting Marked Laboratory Abnormality Criteria From Baseline up to Month 12 - Randomized and Treated Participants
Upper limits of normal (ULL). Leukocytes: \< 2.0\*10\^3 cells per microliter (c/µL); Lymphocytes (absolute): \< 0.5\*10\^3 c/µL; bilirubin: \> 3.0\*ULN milligrams per deciliter (mg/dL); Potassium: \< 3.0 milliequivalents per liter (meq/L) or \> 6.0 meq/L; Magnesium \>2.6 meq/L; Sodium: \< 130 meq/L; Phosphorus: \< 2.0 mg/dL; Uric Acid: \> 10 mg/dL. Baseline = value at screening.
Time frame: Baseline up to Month 12
Long Term Period: Mean Change From Baseline to 54 Months Post Randomization in Calculated GFR on Imputed Values at Specified Timepoints - Intent to Treat (ITT) Participants Who Entered LT Period
ITT=participants randomized to their original treatment arm and who entered the LT period are presented. Baseline=value at screening. Calculated GFR assessment used the MDRD formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value of 0 was imputed and carried forward after death or graft loss up to the end of the analysis period. Sponsor discontinued the CNI treatment arm in Year 3, and participants treated with CNI could elect to switch to belatacept. If a participant did not switch to belatacept, they were required to discontinue from the study. Therefore, efficacy results from Month 36 through Month 54 are difficult to interpret. No formal comparisons were planned between the belatacept and CNI treatment groups post Month 36, and the data up to the final database lock should be interpreted with caution.
Time frame: Baseline, Month 3, 6, 12, 18, 24, 30, 36, 42, 48, 54
Long Term Period: Number of Participants With Acute Rejection (AR) - All Randomized Participants in LT Period
AR was defined: if either a or b was satisfied: (a) the reason for clinical suspicion was reported to be an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness and the episode was a case of biopsy proven AR (AR of Banff histopathologic classification grade IA or higher as assessed by the blinded central pathologist); (b) the reason for clinical suspicion was reported to be something other than: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness; the episode was a case of biopsy proven AR, and the participant was treated for this episode. Banff 97 working classification of kidney transplant pathology was used to categorize the severity of the AR.
Time frame: Post Month 12 up to Year 6 of the Study
Long Term Period: Number of Participants Who Survived With a Functioning Graft or Survived With Pure Graft Loss or Death With Functioning Graft - ITT Participants Who Entered the LT Period
Graft loss = either pure graft loss (participant survived to the end of the study period after graft loss) or death with functioning graft. Pure graft loss = either functional loss or physical loss. Functional loss = a sustained level of serum creatinine (SCr) ≥ 6.0 mg/dL (530 μmol/L) for ≥ 4 weeks or administration of a maintenance dialysis regimen for at least 56 days or impairment of renal function to such a degree that the participant undergoes re-transplantation. The table was designed with built-in redundancy to capture all possible combinations of death and/or graft loss, but not all lines can be summed to reach the total number surviving and the total number who die and/or lose grafts. If a participant experiences pure graft loss and dies at a later date independent of the graft loss event, they are counted only once in the cumulative tabulation of death or graft loss. Only the first event experienced by the participant counted toward the cumulative total.
Time frame: Post Months 24, 36, 48, up to Year 6 of the Study
Long Term Period: Percentage of Participants With New Onset Diabetes Mellitus Up to Month 36- All Randomized Participants Who Entered LT Period
A participant who did not have diabetes prior to randomization is determined to have new onset diabetes mellitus if they received an antidiabetic medication for a duration of at least 30 days or at least two fasting plasma glucose (FPG) tests indicated that FPG is \>=126 mg/dL. Percentage was the number of participants with new onset of diabetes mellitus divided by the number of participants without pre-randomization diabetes.
Time frame: Baseline (screening) up to Month 36 post randomization
Long Term Period: Number of Participants With SAEs, Death, Discontinuation Due to AEs - All Randomized Participants Who Entered the Long Term Period
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.
Time frame: First dose after randomization (Day 1) to 56 days post last dose, up to Year 6 of the Study
Long Term Period: Number of Participants With AEs of Special Interest - All Randomized Participants Who Entered the Long Term Period
Prospectively identified events of special interest which were a subset of all AEs, and were either SAEs or non-serious AEs, included the following categories: Serious Infections, Thrombolic/embolic events, Autoimmune Disease, Malignancy, Peri-infusional reactions (only belatacept treatment group was IV) , Acute Peri-infusional events occurring within 24 hours of injection, Pulmonary Edema and Congestive Heart Failure. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Time frame: First dose after randomization (Day 1) to last dose, plus 56 days, up to Year 6 of the Study
Long Term Period: Mean Change From Baseline to Month 54 in Serum Creatinine- ITT Participants Who Entered LT Period
Baseline was value at screening. Serum creatinine was measured in mg/dL. Only participants who entered into Long Term Period were included in the analysis.
Time frame: Baseline, Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54
Long Term Period: Number of Participants Meeting Marked Laboratory Abnormality Criteria - All ITT Participants Who Entered the Long Term Period
Upper limits of normal (ULN). Hemoglobin: \< 8 g/dL; Platelet count: \< 50\*10\^9 c/L; Leukocytes: \< 2.0\*10\^3 c/µL; Lymphocytes (absolute): \< 0.5\*10\^3 c/µL; Neutrophils: \< 1.0\*10\^3 c/µL; Alanine Aminotransferase (ALT): \> 5.0\*ULN Units per liter (U/L); bilirubin: \> 3.0\*ULN mg/dL; Creatinine: \> 3.0\*ULN mg/dL; Calcium: \< 7 mg/dL; Bicarbonate: \> 12.5 mg/dL; Potassium: \< 3.0 meq/L or \> 6.0 meq/L; Magnesium \>2.6 meq/L; Sodium: \< 130 meq/L; Phosphorus: \< 2.0 mg/dL; Uric Acid: \> 10 mg/dL.
Time frame: Baseline (Screening), up to Year 6 of the Study
Long Term Period: Mean Change From Baseline to Month 54 in Systolic Blood Pressure
Blood pressure was measured while the participant was sitting quietly for 5 minutes and was measured in millimeters of mercury (mmHg). Baseline was value at screening. Only those participants who entered long term period were evaluated.
Time frame: Baseline, Months 6, 12, 18, 24, 30, 36, 42, 48, 54
Long Term Period: Mean Change From Baseline to Month 54 in Diastolic Blood Pressure
Blood pressure was measured while the participant was sitting quietly for 5 minutes and was measured in mmHg. Baseline was value at screening. Only those participants who entered long term period were evaluated.
Time frame: Baseline, Months 6, 12, 18, 24, 30, 36, 42, 48, 54
Participants Who Switched From CNI to Belatacept in Long Term Period : Mean Change in Calculated GFR Based on Imputed Values From Day of Switch to Week 96 Post Switch
Calculated GFR assessment used the MDRD formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value 10 was used, for other participants who had a post baseline cGFR value missing, but had baseline value and at least 2 post baseline values available, which were at least 120 days apart, linear regression model was used to impute the cGFR value. Day of Switch = the first belatacept infusion day.
Time frame: Day of Switch (first belatacept dose) to Week 96 Post Switch
Participants Who Switched to Belatacept in Long Term Period: Number of Participants With AEs and SAEs
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Day of Switch = the first belatacept infusion day.
Time frame: Day of Switch (first dose of belatacept ) to last dose plus 56 days, up to Year 6 of the Study
| Milestone | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Started | 84 | 89 |
| Completed | 83 | 88 |
| Not completed | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Started | 83 | 88 |
| Completed | 81 | 86 |
| Not completed | 2 | 2 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Non-specified | 0 | 1 |
| Milestone | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Started | 81 | 81 |
| Completed | 70 | 64 |
| Not completed | 11 | 17 |
| Withdrew: Adverse event | 1 | 5 |
| Withdrew: Withdrawal by subject | 4 | 7 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 4 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Non-specified | 1 | 2 |
| Milestone | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Started | 38 | 0 |
| Completed | 32 | 0 |
| Not completed | 6 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Adverse event | 4 | 0 |
Calculated GFR assessment used the modification of diet in renal disease (MDRD) formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value 10 was used, for other participants who had a post baseline cGFR value missing, but had baseline value and at least 2 post baseline values available, which were at least 120 days apart, linear regression model was used to impute the cGFR value. Baseline = value at screening.
| mL/min/1.73 m^2 | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Mean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 6 Months Post Randomization - All Randomized Participants (Intent-to-Treat Population) | 6.9 ± 11.97 | 1.1 ± 9.84 |
AR defined: if either a or b was satisfied: a: the reason for clinical suspicion was reported to be an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness and the episode was a case of biopsy proven AR (AR of Banff histopathologic classification Grade IA or higher as assessed by the blinded central pathologist); b: the reason for clinical suspicion was reported to be something other than: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness; the episode was a case of biopsy proven AR, and the participant was treated for this episode. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. AR is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection.
| participants | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Total Number by Month 6 | 6 | 0 |
| By Month 6 Mild Acute (IA) | 1 | 0 |
| Month 6 Mild Acute (IB) | 1 | 0 |
| Month 6 Moderate Acute (IIA) | 3 | 0 |
| Month 6 Moderate Acute (IIB) | 1 | 0 |
| Month 6 Severe Acute (III) | 0 | 0 |
| Total Number by Month 12 | 6 | 0 |
| Month 12 Mild Acute (IA) | 1 | 0 |
| Month 12 Mild Acute (IB) | 1 | 0 |
| Month12 Moderate Acute (IIA) | 3 | 0 |
| Month 12 Moderate Acute (IIB) | 1 | 0 |
| Month 12 Severe Acute (III) | 0 | 0 |
Graft loss was defined as either functional loss or physical loss. Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 mg/dL (530 μmol/L) for ≥ 4 weeks or administration of a maintenance dialysis regimen for at least 56 days or impairment of renal function to such a degree that the participant undergoes re-transplantation.
| percentage of participants | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Month 6 Surviving with Functioning Graft | 100.0 | 98.9 |
| Month 6 Graft Loss or Death | 0.0 | 1.1 |
| Month 6 Graft Loss | 0.0 | 0.0 |
| Month 6 Death | 0.0 | 1.1 |
| Month 6 Death with Functioning Graft | 0.0 | 1.1 |
| Month 12 Surviving with Functioning Graft | 100.0 | 98.9 |
| Month 12 Graft Loss or Death | 0.0 | 1.1 |
| Month 12 Graft Loss | 0.0 | 0.0 |
| Month 12 Death | 0.0 | 1.1 |
| Month 12 Death with Functioning Graft | 0.0 | 1.1 |
Reasons for study drug dose modification included categories of decline in renal function (as determined by the investigator), treatment of acute rejection, and other reasons. More than 1 reason could be given for dose alteration.
| participants | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Number with Dose Alteration (Any Reason) | 15 | 62 |
| Decline in renal function | 0 | 4 |
| Treatment of Acute Rejection | 0 | 0 |
| Other | 15 | 61 |
Calculated GFR assessment used the modification of diet in renal disease (MDRD) formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value 10 was used, for other participants who had a post baseline cGFR value missing, but had baseline value and at least 2 post baseline values available, which were at least 120 days apart, linear regression model was used to impute the cGFR value. Baseline = value at screening. Randomization/First Dose was on Day 1.
| mL/min/1.73 m^2 | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Mean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 12 Months Post Randomization - All Randomized Participants (Intent-to-Treat Population) | 7.0 ± 11.99 | 2.1 ± 10.34 |
Percentage=number with composite divided by number randomized. Graft loss was functional loss or physical loss. Functional loss = sustained level of serum creatinine (SCr) ≥ 6.0 mg/dL for ≥ 4 weeks or administration of a maintenance dialysis regimen for at least 56 days or impairment of renal function to such a degree that participant undergoes re-transplantation. AR: if either a or b: (a) the reason for clinical suspicion was reported to be an unexplained rise of serum creatinine ≥ 25% from baseline; or an unexplained decreased urine output; or fever and graft tenderness and the episode was a case of biopsy-proven AR (grade IA or higher as assessed by the blinded central pathologist); (b) the reason for clinical suspicion was reported to be something other than: an unexplained rise of serum creatinine ≥ 25% from baseline; or an unexplained decreased urine output; or fever and graft tenderness; the episode was a case of biopsy-proven AR, and the participant was treated for it.
| percentage of participants | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Percentage of Participants With a Composite Endpoint of Death, Graft Loss and Acute Rejection at Month 12 | 7.1 (1.6 to 12.7) | 1.1 (0.0 to 6.1) |
A participant who did not have diabetes prior to randomization is determined to have new onset diabetes mellitus if they received an antidiabetic medication for a duration of at least 30 days or at least two fasting plasma glucose (FPG) tests indicated that FPG is \>=126 mg/dL. Percentage was the number of participants with new onset of diabetes mellitus divided by the number of participants without pre-randomization diabetes.
| percentage of participants | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Percentage of Participants With New Onset Diabetes Mellitus - All Randomized Participants | 1.7 (0.0 to 9.1) | 2.9 (0.4 to 10.2) |
Samples were obtained at Day 1 (first dose), Week 24, and Week 52 (or end of therapy). This was a cumulative summary in that once a participant was positive, that participant remained positive for later time points. Evaluation of anti-donor HLA antibodies was performed by an external laboratory (Emory University, Atlanta, Georgia).
| participants | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Baseline (n=80,82) | 3 | 3 |
| Month 6 (n=82,82 | 3 | 4 |
| Month 12 (n=82, 83) | 3 | 4 |
Baseline was value at screening or prior to first dose of study drug. Serum creatinine was measured in milligrams per deciliter (mg/dL). Baseline = value at screening.
| mg/dL | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Month 6 (n=81,82) | -0.1 ± 0.26 | -0.0 ± 0.20 |
| Month 12 (n=81,86) | -0.1 ± 0.28 | -0.0 ± 0.21 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.
| participants | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Deaths | 0 | 1 |
| SAEs | 20 | 17 |
| Treatment Related SAEs | 9 | 4 |
| Discontinued due to SAEs | 1 | 0 |
| Treatment Related AEs | 24 | 27 |
| Discontinued due to AEs | 1 | 0 |
SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire. The subscale in the mental component (MCS) part of the instrument ranged from 1 to 6 with 1=all of the time and 6= none of the time. The subscale for physical component (PCS) ranged from 1 to 3 with 1=Yes, limited a lot and 3=No, not limited at all. The subscale for the extent that physical health or emotional problems interfered with normal activities ranged from 1 to 5 with 1=not at all and 5= extremely. Baseline was at randomization or prior to first dose. Baseline = value at screening. The subscale scores were transformed using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life.
| units on a scale | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| MCS (n=64, 75) | 0.3 ± 1.032 | -0.7 ± 0.959 |
| PCS (n=64, 75) | 0.5 ± 0.808 | 0.8 ± 0.752 |
SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 8 domains of physical and mental component summaries: physical function, role limitations due to physical problems, pain, general health perception, and vitality, social function, role limitations due to emotional problems, and mental health. All domains were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life.
| units on a scale | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Bodily Pain (n=74,79) | 0.7 ± 0.979 | 0.3 ± 0.950 |
| General Health (n=75,79) | 1.6 ± 0.921 | 0.9 ± 0.900 |
| Mental Health (n=73,79) | 0.7 ± 0.913 | -0.1 ± 0.881 |
| Physical Functioning (n=67,75) | -0.5 ± 0.840 | 0.8 ± 0.800 |
| Role Emotional (n=75,79) | -1.4 ± 1.043 | -0.4 ± 1.021 |
| Role Physical (n=75,79) | 0.5 ± 0.961 | 0.2 ± 0.939 |
| Social Functioning (n=75,79) | 0.9 ± 0.929 | -0.5 ± 0.906 |
| Vitality (n=73,79) | 0.2 ± 0.973 | -0.2 ± 0.940 |
The Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-59R) was used to assess the occurrence (never, occasionally, regularly, almost always, always) and distress (0=no distress to 4=terrible distress) of symptoms associated with immunosuppressive therapies. Ridit (relative to an identified distribution) analysis (Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley \& Sons, Inc. 1991) was used. Ridit scores were calculated at 12 months for overall symptom occurrence score and overall symptom distress. The Ridit score reflects the probability that a score observed for an individual randomly selected from a group would be higher (worse symptom) than a score observed for a randomly selected individual from the reference group. The reference group was constituted by the frequency distribution of the responses of all participants on all items at baseline. The ridit of the reference group is by definition, 0.5.
| Ridit score | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Symptom Distress (n=46,44) | 0.5162 | 0.5014 |
| Symptom Occurrence (n=46,45) | 0.5074 | 0.4998 |
Upper limits of normal (ULL). Leukocytes: \< 2.0\*10\^3 cells per microliter (c/µL); Lymphocytes (absolute): \< 0.5\*10\^3 c/µL; bilirubin: \> 3.0\*ULN milligrams per deciliter (mg/dL); Potassium: \< 3.0 milliequivalents per liter (meq/L) or \> 6.0 meq/L; Magnesium \>2.6 meq/L; Sodium: \< 130 meq/L; Phosphorus: \< 2.0 mg/dL; Uric Acid: \> 10 mg/dL. Baseline = value at screening.
| participants | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Leukocytes Low | 0 | 1 |
| Lymphocytes Low | 4 | 0 |
| Bilirubin High | 0 | 1 |
| Potassium Low | 1 | 1 |
| Potassium High | 1 | 0 |
| Magnesium High | 5 | 1 |
| Sodium Low | 1 | 1 |
| Phosphorus Inorganic Low | 5 | 2 |
| Uric Acid High | 4 | 6 |
ITT=participants randomized to their original treatment arm and who entered the LT period are presented. Baseline=value at screening. Calculated GFR assessment used the MDRD formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value of 0 was imputed and carried forward after death or graft loss up to the end of the analysis period. Sponsor discontinued the CNI treatment arm in Year 3, and participants treated with CNI could elect to switch to belatacept. If a participant did not switch to belatacept, they were required to discontinue from the study. Therefore, efficacy results from Month 36 through Month 54 are difficult to interpret. No formal comparisons were planned between the belatacept and CNI treatment groups post Month 36, and the data up to the final database lock should be interpreted with caution.
| mL/min/1.73 m^2 | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Month 3 (n=81, 81) | 5.1 ± 10.16 | 0.4 ± 9.92 |
| Month 6 (n=80, 77) | 7.1 ± 11.94 | 2.3 ± 8.95 |
| Month 12 (n=81, 81) | 7.1 ± 12.02 | 2.8 ± 9.70 |
| Month 18 (n=81, 75) | 8.8 ± 13.88 | 0.1 ± 12.47 |
| Month 24 (n=81, 78) | 8.8 ± 13.77 | -0.0 ± 14.84 |
| Month 30 (n=80, 69) | 9.1 ± 16.10 | 0.1 ± 14.45 |
| Month 36 (n=57, 52) | 7.7 ± 15.91 | 3.9 ± 17.46 |
| Month 42 (n=71, 54) | 9.1 ± 17.56 | 0.6 ± 17.04 |
| Month 48 (n=16, 32) | -1.7 ± 32.15 | 4.2 ± 18.03 |
| Month 54 (n=14, 26) | -0.9 ± 35.69 | 2.4 ± 18.72 |
AR was defined: if either a or b was satisfied: (a) the reason for clinical suspicion was reported to be an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness and the episode was a case of biopsy proven AR (AR of Banff histopathologic classification grade IA or higher as assessed by the blinded central pathologist); (b) the reason for clinical suspicion was reported to be something other than: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness; the episode was a case of biopsy proven AR, and the participant was treated for this episode. Banff 97 working classification of kidney transplant pathology was used to categorize the severity of the AR.
| participants | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Total Number | 5 | 4 |
| Mild Acute IA | 0 | 0 |
| Mild Acute IB | 1 | 1 |
| Moderate Acute IIA | 3 | 2 |
| Moderate Acute IIB | 1 | 1 |
| Severe Acute III | 0 | 0 |
Graft loss = either pure graft loss (participant survived to the end of the study period after graft loss) or death with functioning graft. Pure graft loss = either functional loss or physical loss. Functional loss = a sustained level of serum creatinine (SCr) ≥ 6.0 mg/dL (530 μmol/L) for ≥ 4 weeks or administration of a maintenance dialysis regimen for at least 56 days or impairment of renal function to such a degree that the participant undergoes re-transplantation. The table was designed with built-in redundancy to capture all possible combinations of death and/or graft loss, but not all lines can be summed to reach the total number surviving and the total number who die and/or lose grafts. If a participant experiences pure graft loss and dies at a later date independent of the graft loss event, they are counted only once in the cumulative tabulation of death or graft loss. Only the first event experienced by the participant counted toward the cumulative total.
| participants | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Month 24 Surviving with Functioning Graft | 80 | 80 |
| Month 24 Graft Loss or Death | 1 | 1 |
| Month 24 Graft Loss | 1 | 1 |
| Month 24 Death | 0 | 0 |
| Month 36 Surviving with Functioning Graft | 79 | 80 |
| Month 36 Graft Loss or Death | 2 | 1 |
| Month 36 Graft Loss | 1 | 1 |
| Month 36 Death | 1 | 0 |
| Month 36 Death with Functioning Graft | 1 | 0 |
| Month 48 Surviving with Functioning Graft | 78 | 80 |
| Month 48 Graft Loss or Death | 3 | 1 |
| Month 48 Graft Loss | 1 | 1 |
| Month 48 Death | 2 | 0 |
| Month 48 Death with Functioning Graft | 2 | 0 |
| up to year 6 Surviving with Functioning Graft | 76 | 80 |
| up to year 6 Graft Loss or Death | 5 | 1 |
| up to year 6 Graft Loss | 1 | 1 |
| up to year 6, Death | 4 | 0 |
| up to year 6 Death with Functioning Graft | 4 | 0 |
A participant who did not have diabetes prior to randomization is determined to have new onset diabetes mellitus if they received an antidiabetic medication for a duration of at least 30 days or at least two fasting plasma glucose (FPG) tests indicated that FPG is \>=126 mg/dL. Percentage was the number of participants with new onset of diabetes mellitus divided by the number of participants without pre-randomization diabetes.
| percentage of participants | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Long Term Period: Percentage of Participants With New Onset Diabetes Mellitus Up to Month 36- All Randomized Participants Who Entered LT Period | 6.9 (1.9 to 16.7) | 4.8 (1.0 to 13.5) |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.
| participants | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Deaths | 4 | 0 |
| SAEs | 45 | 40 |
| Treatment Related SAEs | 18 | 14 |
| Discontinued Due to SAEs | 1 | 2 |
| Treatment Related AEs | 38 | 43 |
| Discontinued Due to AEs | 1 | 3 |
Prospectively identified events of special interest which were a subset of all AEs, and were either SAEs or non-serious AEs, included the following categories: Serious Infections, Thrombolic/embolic events, Autoimmune Disease, Malignancy, Peri-infusional reactions (only belatacept treatment group was IV) , Acute Peri-infusional events occurring within 24 hours of injection, Pulmonary Edema and Congestive Heart Failure. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
| participants | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Malignancies | 8 | 9 |
| Serious Infections | 26 | 26 |
| Thrombolic/embolic | 3 | 0 |
| Peri-infusional Events | 37 | 0 |
| Acute Peri-infusional Events | 5 | 0 |
| Autoimmune Disease | 2 | 1 |
| Pulmonary Edema/Congestive Heart Failure | 3 | 2 |
Baseline was value at screening. Serum creatinine was measured in mg/dL. Only participants who entered into Long Term Period were included in the analysis.
| mg/dL | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Month 3 (n=81,81) | -0.1 ± 0.24 | 0.0 ± 0.21 |
| Month 6 (n=81,77) | -0.1 ± 0.26 | -0.0 ± 0.19 |
| Month 12 (n=81,81) | -0.1 ± 0.28 | -0.0 ± 0.21 |
| Month 18 (n=80,75) | -0.1 ± 0.31 | 0.1 ± 0.77 |
| Month 24 (n=80,77) | -0.1 ± 0.28 | 0.0 ± 0.37 |
| Month 30 (n=78, 68) | -0.2 ± 0.35 | 0.0 ± 0.32 |
| Month 36 (n=55, 51) | -0.1 ± 0.29 | -0.0 ± 0.39 |
| Month 42 (n=68, 53) | -0.2 ± 0.30 | 0.0 ± 0.41 |
| Month 48 (n=12, 31) | -0.2 ± 0.16 | -0.1 ± 0.30 |
| Month 54 (n=10, 25) | -0.3 ± 0.25 | -0.1 ± 0.29 |
Upper limits of normal (ULN). Hemoglobin: \< 8 g/dL; Platelet count: \< 50\*10\^9 c/L; Leukocytes: \< 2.0\*10\^3 c/µL; Lymphocytes (absolute): \< 0.5\*10\^3 c/µL; Neutrophils: \< 1.0\*10\^3 c/µL; Alanine Aminotransferase (ALT): \> 5.0\*ULN Units per liter (U/L); bilirubin: \> 3.0\*ULN mg/dL; Creatinine: \> 3.0\*ULN mg/dL; Calcium: \< 7 mg/dL; Bicarbonate: \> 12.5 mg/dL; Potassium: \< 3.0 meq/L or \> 6.0 meq/L; Magnesium \>2.6 meq/L; Sodium: \< 130 meq/L; Phosphorus: \< 2.0 mg/dL; Uric Acid: \> 10 mg/dL.
| participants | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Hemoglobin Low | 1 | 0 |
| Platelet Count Low | 1 | 1 |
| Leukocytes Low | 0 | 1 |
| Lymphocytes Low | 5 | 5 |
| Neutrophils Low | 1 | 2 |
| ALT High | 0 | 1 |
| Bilirubin High | 0 | 1 |
| Creatinine High | 0 | 1 |
| Calcium Low | 0 | 2 |
| Bicarbonate Low | 0 | 1 |
| Potassium Low | 2 | 1 |
| Potassium High | 1 | 3 |
| Magnesium High | 6 | 1 |
| Sodium Low | 2 | 1 |
| Phosphorus Inorganic Low | 7 | 3 |
| Uric Acid High | 7 | 7 |
Blood pressure was measured while the participant was sitting quietly for 5 minutes and was measured in millimeters of mercury (mmHg). Baseline was value at screening. Only those participants who entered long term period were evaluated.
| mmHg | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Month 6 (n=78,73) | -3.6 ± 19.06 | -0.4 ± 17.52 |
| Month 12 (n=77,71) | -4.6 ± 18.33 | -4.2 ± 16.26 |
| Month 18 (n=77,1) | -4.4 ± 17.40 | 9.0 ± NA |
| Month 24 (n=77,1) | -6.0 ± 17.94 | 4.0 ± NA |
| Month 30 (n=75, 6) | -3.6 ± 17.94 | -0.5 ± 20.78 |
| Month 36 (n=75,13) | -6.6 ± 17.49 | 1.2 ± 13.61 |
| Month 42 (n=74, 29) | -5.4 ± 17.08 | -3.5 ± 19.33 |
| Month 48 (n=73,32) | -4.4 ± 16.16 | -3.7 ± 14.35 |
| Month 54 (n=72,33) | -4.9 ± 16.90 | -3.8 ± 12.96 |
Blood pressure was measured while the participant was sitting quietly for 5 minutes and was measured in mmHg. Baseline was value at screening. Only those participants who entered long term period were evaluated.
| mmHg | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) |
|---|---|---|
| Month 6 (n=78,73) | -2.0 ± 10.78 | -2.2 ± 10.50 |
| Month 12 (n=77,71) | -2.5 ± 11.54 | -1.0 ± 11.04 |
| Month 18 (n=77,1) | -1.7 ± 11.79 | 10.0 ± NA |
| Month 24 (n=77,1) | -3.9 ± 10.19 | 13.0 ± NA |
| Month 30 (n=75,6) | -1.8 ± 10.97 | 5.7 ± 9.14 |
| Month 36 (n=75,13) | -1.9 ± 10.86 | -1.6 ± 7.69 |
| Month 42 (n=74,29) | -1.7 ± 11.70 | -3.8 ± 10.99 |
| Month 48 (n=73, 32) | -3.2 ± 10.53 | -3.6 ± 11.92 |
| Month 54 (n=72, 33) | -1.1 ± 10.86 | -3.6 ± 11.72 |
Calculated GFR assessment used the MDRD formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value 10 was used, for other participants who had a post baseline cGFR value missing, but had baseline value and at least 2 post baseline values available, which were at least 120 days apart, linear regression model was used to impute the cGFR value. Day of Switch = the first belatacept infusion day.
| mL/min/1.73 m^2 | Belatacept 5 mg/kg in Participants Switched During LT Period |
|---|---|
| Week 4 Post Switch (n=30) | 1.3 ± 5.85 |
| Week 12 Post Switch (n=33) | 3.3 ± 9.88 |
| Week 24 Post Switch (n= 29) | 2.1 ± 10.66 |
| Week 48 Post Switch (n= 12) | 0.3 ± 7.75 |
| Week 96 Post Switch (n= 8) | 0.1 ± 10.33 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Day of Switch = the first belatacept infusion day.
| participants | Belatacept 5 mg/kg in Participants Switched During LT Period |
|---|---|
| AEs | 32 |
| SAEs | 9 |
Collected over Date of first dose to 56 days post final dose, up to June 2013 (approximately 80 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belatacept 5 mg/kg | — | 45/83 (54.2%) | 78/83 (94%) |
| Calcineurin Inhibitor (CNI) | — | 40/88 (45.5%) | 74/88 (84.1%) |
| Belatacept 5 mg/kg in Participants Switched During LT Period | — | 9/38 (23.7%) | 27/38 (71.1%) |
| Event | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) | Belatacept 5 mg/kg in Participants Switched During LT Period |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 8/83 | 1/88 | 0/38 |
| PyrexiaGeneral disorders | 5/83 | 2/88 | 1/38 |
| GastroenteritisInfections and infestations | 5/83 | 2/88 | 0/38 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/83 | 3/88 | 2/38 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/83 | 4/88 | 1/38 |
| PneumoniaInfections and infestations | 3/83 | 3/88 | 0/38 |
| Blood creatinine increasedInvestigations | 2/83 | 3/88 | 1/38 |
| Renal failure acuteRenal and urinary disorders | 1/83 | 3/88 | 0/38 |
| Cardiac failure congestiveCardiac disorders | 2/83 | 0/88 | 1/38 |
| NephropathyRenal and urinary disorders | 0/83 | 0/88 | 1/38 |
| Event | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) | Belatacept 5 mg/kg in Participants Switched During LT Period |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 36/83 | 25/88 | 5/38 |
| CoughRespiratory, thoracic and mediastinal disorders | 27/83 | 17/88 | 3/38 |
| NasopharyngitisInfections and infestations | 21/83 | 12/88 | 3/38 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 20/83 | 7/88 | 2/38 |
| Oedema peripheralGeneral disorders | 20/83 | 7/88 | 1/38 |
| Urinary tract infectionInfections and infestations | 19/83 | 10/88 | 9/38 |
| HypertensionVascular disorders | 19/83 | 7/88 | 4/38 |
| Upper respiratory tract infectionInfections and infestations | 19/83 | 11/88 | 1/38 |
| AnaemiaBlood and lymphatic system disorders | 18/83 | 12/88 | 1/38 |
| HeadacheNervous system disorders | 16/83 | 9/88 | 2/38 |
Participants randomized to a treatment arm.
| Age, Continuous(years) | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) | Total |
|---|---|---|---|
| Mean | 45.3 ± 13.5 | 44.3 ± 13.0 | 44.8 ± 13.2 |
| Age, Customized(participants) | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) | Total |
|---|---|---|---|
| 18 - 45 years | 42 | 47 | 89 |
| 46 - 65 years | 37 | 36 | 73 |
| Greater than (>) 65 years | 5 | 6 | 11 |
| Gender(Participants) | Belatacept 5 mg/kg | Calcineurin Inhibitor (CNI) | Total |
|---|---|---|---|
| Female | 18 | 29 | 47 |
| Male | 66 | 60 | 126 |
The record gives a start of Jan 2007, a primary completion of Jun 2009 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 7 years 7 months after primary completion. A results delay was requested in Apr 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept